Cargando…
Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections: A Meta-analysis
BACKGROUND: Antimicrobial resistance is on the rise. The use of redundant and inappropriate antibiotics is contributing to recurrent infections and resistance. Newer antibiotics with more robust coverage for Gram-negative bacteria are in great demand for complicated urinary tract infections (cUTIs),...
Autores principales: | Sahra, Syeda, Jahangir, Abdullah, Hamadi, Rachelle, Jahangir, Ahmad, Glaser, Allison |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258290/ https://www.ncbi.nlm.nih.gov/pubmed/34216121 http://dx.doi.org/10.3947/ic.2021.0051 |
Ejemplares similares
-
Reply: Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections
por: Jahangir, Abdullah, et al.
Publicado: (2021) -
Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections
por: Vaziri, Ali Zaman, et al.
Publicado: (2021) -
New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022) -
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021) -
1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)